The Pharmacogenetic and Pathological assessment of CYP2C19 activity in patients
with advanced cancer
Registration number:
|
ACTRN12605000393651 |
Ethics number:
|
NTX/05/07/083 |
This study is looking at the effect of cancer and genetic profiles on the function
of an enzyme involved in the metabolism of the chemotherapy drug cyclosphosphamide.
Progress
This study has now closed to accrual with a total of 33 patients. Thank you to
the Auckland
and Wellington sites for their contribution.
Results
NA Helsby, W-Y Lo, K Sharples, G Riley, M Murray, K Spells, M Dzhelai, A Simpson
and M Findlay 'CYP2C19 pharmacogenetics in advanced cancer: compromised function
independent of genotype' British Journal of Cancer (2008) 99, 1251 –
1255
This paper has been highlighted as a favourite paper on the NIH funded Pharmacogenetics
and Pharmacogenomics Knowledge Base
Centres involved
- The University of Auckland
- Wellington Hospital
